Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients
Marcucci, Guido , Maharry, Kati , Metzeler, Klaus H. , Wu, Yue-Zhong, Mrózek, Krzysztof , Kohlschmidt, Jessica, Whitman, Susan P., Schwind, Sebastian , Becker, Heiko , Eisfeld, Ann‐Kathrin , Carroll, Andrew J. , Powell, Bayard L., Kolitz, Jonathan E. , Garzon, Ramiro , Stone, Richard M. , Bloomfield, Clara D. , Volinia, Stefano , Nicolet, Deedra , Mendler, Jason H. , Caligiuri, Michael A.

Journal of Clinical Oncology | May 7, 2013 | Volume: 31 | Issue: 17 | Pages: 2086-2093

10.1200/jco.2012.45.6228 | PMID 23650424 Get It

Purpose To evaluate the impact of miR-155 on the outcome of adults with cytogenetically normal (CN) acute myeloid leukemia (AML) in the context of other clinical and molecular prognosticators and to gain insight into the leukemogenic role of this microRNA. Patients and Methods We evaluated 363 patients with primary CN-AML. miR-155 levels were measured in pretreatment marrow and blood by NanoString nCounter assays that quantified the expression of the encoding gene MIR155HG. All molecular prognosticators were assessed centrally. miR-155–associated gene and microRNA expression profiles were derived using microarrays. Results Considering all patients, high miR-155 expression was associated with a lower complete remission (CR) rate (P < .001) and shorter disease-free survival (P = .001) and overall survival (OS; P < .001) after adjusting for age. In multivariable analyses, high miR-155 expression remained an independent predictor for a lower CR rate (P = .007) and shorter OS (P < .001). High miR-155 expressers had approximately 50% reduction in the odds of achieving CR and 60% increase in the risk of death compared with low miR-155 expressers. Although high miR-155 expression was not associated with a distinct microRNA expression profile, it was associated with a gene expression profile enriched for genes involved in cellular mechanisms deregulated in AML (eg, apoptosis, nuclear factor-κB activation, and inflammation), thereby supporting a pivotal and unique role of this microRNA in myeloid leukemogenesis. Conclusion miR-155 expression levels are associated with clinical outcome independently of other strong clinical and molecular predictors. The availability of emerging compounds with antagonistic activity to microRNAs in the clinic provides the opportunity for future therapeutic targeting of miR-155 in AML.
Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial
Perez, Edith A. , Dueck, Amylou C. , McCullough, Ann E. , Chen, Beiyun, Geiger, Xochiquetzal J., Jenkins, Robert B. , Lingle, Wilma L., Davidson, Nancy E. , Martino, Silvana, Kutteh, Leila A., Harris, Lyndsay N. , Reinholz, Monica M., Kaufman, Peter A. , Sledge, George W. , Gralow, Julie R. , Dueck, A. C.

Journal of Clinical Oncology | May 7, 2013 | Volume: 31 | Issue: 17 | Pages: 2115-2122

10.1200/jco.2012.42.2642 | PMID 23650412 Get It

Purpose It has been suggested that PTEN, a negative regulator of PI3K/AKT signaling, is involved in tumor sensitivity to trastuzumab. We investigated the association between tumor PTEN protein expression and disease-free survival (DFS) of patients randomly assigned to receive chemotherapy alone (arm A) or chemotherapy with sequential (arm B) or concurrent trastuzumab (arm C) in the phase III early-stage human epidermal growth factor receptor 2 (HER2) –positive trial—North Central Cancer Treatment Group (NCCTG) N9831. Patients and Methods The intensity and percentage of invasive cells with cytoplasmic PTEN staining were determined in tissue microarray sections containing three cores per block (n = 1,286) or in whole tissue sections (WS; n = 516) by using standard immunohistochemistry (138G6 monoclonal antibody). Tumors were considered positive for PTEN (PTEN-positive) if any core or WS had any invasive cells with ≥ 1+ staining. Median follow-up was 6.0 years. Results Of 1,802 patients included in this analysis (of 3,505 patients registered to N9831), 1,342 (74%) had PTEN-positive tumors. PTEN positivity was associated with hormone receptor negativity (χ2 P < .001) and nodal positivity (χ2 P = .04). PTEN did not have an impact on DFS within the various arms. Comparing DFS of arm C to arm A, patients with PTEN-positive and PTEN-negative tumors had hazard ratios (HRs) of 0.65 (P = .003) and 0.47 (P = .005), respectively (interaction P = .16). For arm B versus arm A, patients with PTEN-positive and PTEN-negative tumors had HRs of 0.70 (P = .009) and 0.85 (P = .44), respectively (interaction P = .47). Conclusion In contrast to selected preclinical and limited clinical studies suggesting a decrease in trastuzumab sensitivity in patients with PTEN-negative tumors, our data show benefit of adjuvant trastuzumab for patients with HER2-positive breast cancer, independent of tumor PTEN status.
Human Leukocyte Antigens and Cellular Immune Responses to Anthrax Vaccine Adsorbed
Ovsyannikova, Inna G. , Vierkant, Robert A. , Pajewski, Nicholas M., Quinn, Conrad P. , Kaslow, Richard A., Jacobson, Robert M. , Pankratz, V. Shane , Poland, Gregory A. , Vierkant, Robert A , Jacobson, Robert M

Infection and Immunity | May 7, 2013 | Volume: 81 | Issue: 7 | Pages: 2584-2591

10.1128/iai.00269-13 | PMID 23649091 Get It

ABSTRACT Interindividual variations in vaccine-induced immune responses are in part due to host genetic polymorphisms in the human leukocyte antigen (HLA) and other gene families. This study examined associations between HLA genotypes, haplotypes, and homozygosity and protective antigen (PA)-specific cellular immune responses in healthy subjects following immunization with Anthrax Vaccine Adsorbed (AVA). While limited associations were observed between individual HLA alleles or haplotypes and variable lymphocyte proliferative (LP) responses to AVA, analyses of homozygosity supported the hypothesis of a “heterozygote advantage.” Individuals who were homozygous for any HLA locus demonstrated significantly lower PA-specific LP than subjects who were heterozygous at all eight loci (median stimulation indices [SI], 1.84 versus 2.95, P = 0.009). Similarly, we found that class I (HLA-A) and class II (HLA-DQA1 and HLA-DQB1) homozygosity was significantly associated with an overall decrease in LP compared with heterozygosity at those three loci. Specifically, individuals who were homozygous at these loci had significantly lower PA-specific LP than subjects heterozygous for HLA-A (median SI, 1.48 versus 2.13, P = 0.005), HLA-DQA1 (median SI, 1.75 versus 2.11, P = 0.007), and HLA-DQB1 (median SI, 1.48 versus 2.13, P = 0.002) loci, respectively. Finally, homozygosity at an increasing number (≥4) of HLA loci was significantly correlated with a reduction in LP response ( P < 0.001) in a dose-dependent manner. Additional studies are needed to reproduce these findings and determine whether HLA-heterozygous individuals generate stronger cellular immune response to other virulence factors ( Bacillus anthracis LF and EF) than HLA-homozygous subjects.
A critical analysis of the surgical outcomes for the treatment of Peyronie’s disease
Mandava, Sree Harsha , Trost, Landon , Hellstrom, Wayne J.G.

Arab Journal of Urology | May 6, 2013 | Volume: 11 | Issue: 3 | Pages: 284-293

10.1016/j.aju.2013.03.007 | PMID 26558094 Get It

Variation in the Prevalence of Sarcopenia and Sarcopenic Obesity in Older Adults Associated with Different Research Definitions: Dual‐Energy X ‐Ray Absorptiometry Data from the N
Barré, Laura , MacKenzie, Todd A. , Pratt, Sarah I. , Bartels, Stephen J. , Batsis, John A. , López-Jiménez, Francisco

Journal of the American Geriatrics Society | May 6, 2013 | Volume: 61 | Issue: 6 | Pages: 974-980

10.1111/jgs.12260 | PMID 23647372 Get It

Objectives To determine the prevalence range for sarcopenic obesity and its relationship with sex, age, and ethnicity. Design Cross‐sectional analysis of a population‐based sample. Setting Noninstitutionalized persons in the U nited S tates participating in the N ational H ealth and N utrition E xamination S urveys 1999–2004. Participants Subsample of 4,984 subjects aged 60 and older with dual‐energy X‐ray absorptiometry body composition data. Measurements Eight definitions of sarcopenic obesity identified from six studies found using a systematic literature review ( B aumgartner, B ouchard, D avison, Z oico, L evine, K im‐1,2,3) were applied to the sample. Results were stratified according to sex, age, and ethnicity. Results Prevalence of sarcopenic obesity ranged from 4.4% to 84.0% in men and from 3.6% to 94.0% in women. Prevalence was higher in men using definitions from Baumgartner (17.9% vs 13.3%, P < .001), Levine (14.2% vs 6.6%, P < .001), and Kim‐1 (30.0% vs 9.3%, P < .001); lower for men using the Davison (4.4% vs 11.1%, P < .001) and Kim‐2 (83.7% vs 94.0%) definitions; and the same for men and women using the Bouchard (45.3% vs 44.3%, P = .32) and Kim‐3 (75.6% vs 77.0%, P = .51) definitions. For all but one definition, sarcopenic obesity increased with each decade and was lower in non‐ H ispanic blacks than whites. Conclusion Prevalence of sarcopenic obesity in older adults varies up to 26‐fold depending on current research definitions. Such a high degree of variability suggests the need to establish consensus criteria that can be reliably applied across clinical and research settings.
Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma
Greenberg, Alexandra J. , Cousin, Margot A. , Kumar, Shaji , Ketterling, Rhett P. , Knudson, Ryan A., Colby, Colin , Scott, Christopher G. , Vachon, Celine M. , Rajkumar, S. Vincent , Larson, Dirk R. , Vachon, Celine M. , Rajkumar, S Vincent , Scott, Christopher , Ketterling, Rhett P

European Journal of Haematology | May 6, 2013 | Volume: 91 | Issue: 3 | Pages: 193-195

10.1111/ejh.12133 | PMID 23647020 Get It

AbstractWe previously reported an increased risk of monoclonal gammopathy of undetermined significance (MGUS) in first‐degree relatives of MGUS and multiple myeloma patients. Here, we examine whether primary cytogenetic categories of myeloma differ between patients with and without a family history of MGUS or myeloma. We studied 201 myeloma patients with available data on family history and molecular cytogenetic classification. Myeloma with trisomies was more common in probands who had an affected first‐degree relative with MGUS or myeloma compared with those without a family history (46.9% vs. 33.5%, P = 0.125); however, the difference was not statistically significant. Additional studies on the cytogenetic types of myeloma associated with familial tendency are needed.
The Influence of Prior Median Sternotomy on Outcome of Heart Transplantation
Handa, Nobuhiro , Mussa, Shafi, O’Fallon, W. Michael, Daly, Richard C. , McGregor, Christopher G.A.

Asian Cardiovascular and Thoracic Annals | May 6, 2013 | Volume: 6 | Issue: 1 | Pages: 17-22

10.1177/021849239800600104 Get It

This study is a retrospective analysis of the influence of previous cardiac surgery on the outcome of heart transplantation in 118 consecutive recipients from January 1988 to December 1996. Group 1 consisted of 67 patients who had no previous sternotomy, group 2 was 33 patients who had one previous sternotomy, and group 3 was 18 patients who had two or more previous sternotomies. The three groups were demographically similar apart from the indication for transplantation and the sex distribution. Preoperative hemodynamic data, except systolic pulmonary artery pressure, were similar among the three groups. There was no significant difference in hospital mortality, 1-year and 5-year actuarial survival rates, incidence of renal dysfunction requiring dialysis, prolonged respiratory support, elevated total bilirubin, re-exploration for bleeding, incidence of mediastinitis, or postoperative hospital stay between the groups. The rejection-free and infection-free survival rates were similar in the three groups. However, previous sternotomy resulted in significantly longer cardiopulmonary bypass times and increased requirement for blood and blood products. The use of a cell saver limited the need for stored red blood cells. This study demonstrated no survival disadvantage of previous sternotomy in patients undergoing heart transplantation.
Video-Assisted Thoracic Surgery
Allen, Mark S.

Asian Cardiovascular and Thoracic Annals | May 6, 2013 | Volume: 3 | Issue: 3-4 | Pages: 93-94

10.1177/021849239500300401 Get It

Importance of Perioperative Blood Glucose Management in Cardiac Surgical Patients
Shine, Timothy, Uchikado, Mihoko, Crawford, Claudia C. , Murray, Michael J.

Asian Cardiovascular and Thoracic Annals | May 6, 2013 | Volume: 15 | Issue: 6 | Pages: 534-538

10.1177/021849230701500621 | PMID 18042786 Get It

Tight blood glucose control has become a therapeutic goal for anesthetic management of patients undergoing cardiovascular surgery. We discuss the evidence for a link between blood glucose levels and rates of morbidity and mortality in cardiac surgical patients in the intensive care unit. Hyperglycemia per se has been associated with higher rates of deep wound infection, neurologic, renal, and cardiac complications following surgery, as well as longer intensive care unit stay. We review the specifics of glucose management in patients undergoing cardiac surgery and hypothermic cardiopulmonary bypass, including the role that insulin may play in regulating blood glucose levels intraoperatively and the relationship between insulin and outcome.
Osteoporosis Screening: The Long Wait for Change
Kling, Juliana M. , Mayer, Anita P. , Westphal, Sydney A., Kling, Juliana M

Journal of Women's Health | May 6, 2013 | Volume: 22 | Issue: 7 | Pages: 649-650

10.1089/jwh.2013.4395 | PMID 23646905 Get It